UK's NICE does not recommend tucatinib for HER2-positive metastatic breast cancer.

Předmět:	HER2 positive breast cancer METASTATIC breast cancer PROTEIN-tyrosine kinase inhibitors BREAST cancer
Zdroj:	PharmacoEconomics & Outcomes News; 11/13/2021, Vol. 891 Issue 1, p37-37, 1p
Abstrakt:	NICE draft guidance does not recommend tucatinib for advanced breast cancer. Despite a lack of treatment options for advanced, HER2-positive breast cancer, UK's National Institute for Health and Care Excellence (NICE) has decided not to recommend the tyrosine kinase inhibitor, tucatinib [TUKYSA; Seagen Inc], in its latest draft guidance. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink